Abatacept
- Generic Name
- Abatacept
- Brand Names
- Orencia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 332348-12-6
- Unique Ingredient Identifier
- 7D0YB67S97
- Background
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of tw...
- Indication
Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and for the treatment of active psoriatic arthritis. In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.
...
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Moderate to Severe Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Psoriatic Arthritis
- Associated Therapies
- -
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris
- Conditions
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT00277225
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Beverly Hills, California, United States
Comparability DE vs CD-CHO1
- Conditions
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT00277199
- Locations
- 🇬🇧
Inveresk Clinical Research, Edinburgh, United Kingdom
Islet Transplantation Using Abatacept
- Conditions
- Interventions
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 5
- Registration Number
- NCT00276250
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)
- Conditions
- Interventions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 87
- Registration Number
- NCT00254293
- Locations
- 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸The Arthritis Clinic & Carolina Bone & Joint, Charlotte, North Carolina, United States
An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT00162201
- Locations
- 🇬🇧
Local Institution, Leeds, Essex, United Kingdom
The Study of Abatacept in Combination With Etanercept
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2010-12-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 141
- Registration Number
- NCT00162279
- Locations
- 🇺🇸
Local Institution, Glendale, Wisconsin, United States
Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy
- Conditions
- Interventions
- First Posted Date
- 2005-07-29
- Last Posted Date
- 2012-02-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1286
- Registration Number
- NCT00124982
- Locations
- 🇬🇧
Local Institution, Leeds, North Yorkshire, United Kingdom
Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 56
- Registration Number
- NCT00124449
- Locations
- 🇬🇧
Local Institution, Leeds, North Yorkshire, United Kingdom
Remission and Joint Damage Progression in Early Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2010-11-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1052
- Registration Number
- NCT00122382
- Locations
- 🇬🇧
Local Institution, Newcastle, Northumberland, United Kingdom
🇺🇸Lion Research, Norman, Oklahoma, United States
🇺🇸Diagnostic Rheumatology And Research, Indianapolis, Indiana, United States
Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone
- Conditions
- Interventions
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 183
- Registration Number
- NCT00119678
- Locations
- 🇺🇸
8737 Beverly Blvd., Los Angeles, California, United States
🇺🇸Office Of Geoffrey S. Dolan, Md, Long Beach, California, United States
🇺🇸Kentuckiana Center For Better Bone And Joint Health, Louisville, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.